PBA 001
Alternative Names: PBA-001Latest Information Update: 28 Apr 2024
At a glance
- Originator Path BioAnalytics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Coeliac disease; Respiratory tract disorders
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Coeliac disease in USA
- 28 Apr 2024 No recent reports of development identified for phase-I development in Respiratory-tract-disorders in USA
- 02 Mar 2021 PBA 001 is available for licensing as of 02 Mar 2021. http://pathbioanalytics.com/#shapely_home_parallax-22